Helen Torley - Oct 8, 2024 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Role
PRESIDENT AND CEO, Director
Signature
/s/ James R. Oehler, Attorney-in-Fact
Stock symbol
HALO
Transactions as of
Oct 8, 2024
Transactions value $
-$1,065,743
Form type
4
Date filed
10/9/2024, 05:39 PM
Previous filing
Sep 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HALO Common Stock Options Exercise $139K +10K +1.48% $13.87 687K Oct 8, 2024 Direct F1
transaction HALO Common Stock Sale -$491K -9.1K -1.33% $53.94 678K Oct 8, 2024 Direct F1, F2
transaction HALO Common Stock Sale -$49.1K -900 -0.13% $54.57 677K Oct 8, 2024 Direct F1, F3
transaction HALO Common Stock Options Exercise $139K +10K +1.48% $13.87 687K Oct 9, 2024 Direct F1
transaction HALO Common Stock Sale -$310K -5.98K -0.87% $51.85 681K Oct 9, 2024 Direct F1, F4
transaction HALO Common Stock Sale -$86.1K -1.62K -0.24% $53.31 679K Oct 9, 2024 Direct F1, F5
transaction HALO Common Stock Sale -$130K -2.4K -0.35% $53.91 677K Oct 9, 2024 Direct F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HALO Option to Purchase Common Stock Options Exercise -$139K -10K -50% $13.87 10K Oct 8, 2024 Common Stock 10K $13.87 Direct F1, F7
transaction HALO Option to Purchase Common Stock Options Exercise -$139K -10K -100% $13.87 0 Oct 9, 2024 Common Stock 10K $13.87 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 22, 2024 in accordance with Rule 10b5-1.
F2 Represents a weighted average sales price per share. The shares were sold at prices ranging from $53.556 to $54.40. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3 Represents a weighted average sales price per share. The shares were sold at prices ranging from $54.56 to $54.575. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4 Represents a weighted average sales price per share. The shares were sold at prices ranging from $51.49 to $52.385. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5 Represents a weighted average sales price per share. The shares were sold at prices ranging from $52.65 to $53.60. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6 Represents a weighted average sales price per share. The shares were sold at prices ranging from $53.66 to $54.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F7 Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 6, 2015.